Clinical trial
Neoadjuvant Pembrolizumab and Carboplatin Plus Paclitaxel for Stage I Triple-negative Breast Cancer
NCT06604858
Study timeline
Study start (actual)2025-05-29Date precision: day
Registry last updated2026-07-27
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Breast Cancerunresolved
Triple Negative Breast Cancerunresolved
Interventions
PembrolizumabDRUG · verified · RxNorm: pembrolizumab
CarboplatinDRUG · verified · RxNorm: carboplatin
PaclitaxelDRUG · verified · RxNorm: paclitaxel
Sponsors & collaborators
MedSIRlead sponsor
Merk Sharp & Dohme España S.A.collaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT06604858 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.